Cargando…

Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study

BACKGROUND: Evidence concerning the potential repurposing of antihypertensives for Alzheimer’s disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Venexia M, Kehoe, Patrick G, Martin, Richard M, Davies, Neil M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751008/
https://www.ncbi.nlm.nih.gov/pubmed/31335937
http://dx.doi.org/10.1093/ije/dyz155
_version_ 1783625587229720576
author Walker, Venexia M
Kehoe, Patrick G
Martin, Richard M
Davies, Neil M
author_facet Walker, Venexia M
Kehoe, Patrick G
Martin, Richard M
Davies, Neil M
author_sort Walker, Venexia M
collection PubMed
description BACKGROUND: Evidence concerning the potential repurposing of antihypertensives for Alzheimer’s disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer’s disease. METHODS: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer’s disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer’s disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. RESULTS: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer’s disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153). CONCLUSIONS: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer’s disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer’s disease, they may not do so via systolic blood pressure.
format Online
Article
Text
id pubmed-7751008
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77510082020-12-28 Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study Walker, Venexia M Kehoe, Patrick G Martin, Richard M Davies, Neil M Int J Epidemiol Mendelian Randomization BACKGROUND: Evidence concerning the potential repurposing of antihypertensives for Alzheimer’s disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer’s disease. METHODS: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer’s disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer’s disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. RESULTS: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer’s disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153). CONCLUSIONS: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer’s disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer’s disease, they may not do so via systolic blood pressure. Oxford University Press 2019-07-23 /pmc/articles/PMC7751008/ /pubmed/31335937 http://dx.doi.org/10.1093/ije/dyz155 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mendelian Randomization
Walker, Venexia M
Kehoe, Patrick G
Martin, Richard M
Davies, Neil M
Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title_full Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title_fullStr Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title_full_unstemmed Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title_short Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
title_sort repurposing antihypertensive drugs for the prevention of alzheimer’s disease: a mendelian randomization study
topic Mendelian Randomization
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751008/
https://www.ncbi.nlm.nih.gov/pubmed/31335937
http://dx.doi.org/10.1093/ije/dyz155
work_keys_str_mv AT walkervenexiam repurposingantihypertensivedrugsforthepreventionofalzheimersdiseaseamendelianrandomizationstudy
AT kehoepatrickg repurposingantihypertensivedrugsforthepreventionofalzheimersdiseaseamendelianrandomizationstudy
AT martinrichardm repurposingantihypertensivedrugsforthepreventionofalzheimersdiseaseamendelianrandomizationstudy
AT daviesneilm repurposingantihypertensivedrugsforthepreventionofalzheimersdiseaseamendelianrandomizationstudy